Alembic Pharmaceuticals Ltd

Alembic Pharma Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Alembic Pharmaceuticals Ltd

₹ 751 3.69%
19 May - close price
alembic-india.com BSE: 533573 NSE: APLLTD
About

Alembic Pharmaceuticals is in the business of development, manufacturing, and marketing of Pharmaceuticals products i.e. Formulations and Active Pharmaceutical Ingredients.
The company has 3 R&D and 5 manufacturing facilities.

Key Points

Leading Pharma company
The company is a leading research-driven, integrated pharmaceutical company specializing in generic formulations across diverse platforms. [1]

Website BSE NSE
  • Market Cap ₹ 14,764 Cr.
  • Current Price ₹ 751
  • High / Low ₹ 1,108 / 635
  • Stock P/E 20.2
  • Book Value ₹ 289
  • Dividend Yield 1.46 %
  • ROCE 12.6 %
  • ROE 13.4 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company has been maintaining a healthy dividend payout of 35.7%

Cons

  • Stock is trading at 2.60 times its book value
  • The company has delivered a poor sales growth of 6.37% over past five years.
  • Tax rate seems low
  • Company has a low return on equity of 12.7% over last 3 years.
  • Company might be capitalizing the interest cost

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
1,406 1,486 1,595 1,631 1,517 1,562 1,648 1,693 1,770 1,711 1,910 1,876 1,848
1,203 1,287 1,387 1,364 1,257 1,325 1,409 1,433 1,498 1,430 1,594 1,585 1,620
Operating Profit 204 199 208 266 260 237 239 260 271 281 316 292 228
OPM % 14% 13% 13% 16% 17% 15% 15% 15% 15% 16% 17% 16% 12%
1 12 10 3 4 2 30 10 14 6 8 -27 2
Interest 14 14 16 15 11 13 19 22 25 24 24 23 23
Depreciation 74 66 68 69 69 69 71 70 69 74 76 80 89
Profit before tax 116 130 135 185 183 157 180 178 192 190 224 162 119
Tax % -31% 7% -1% 2% 3% 14% 15% 23% 18% 19% 18% 18% -70%
153 121 137 180 178 135 153 138 157 154 184 132 202
EPS in Rs 7.76 6.14 6.95 9.18 9.07 6.85 7.80 7.04 7.98 7.85 9.40 6.76 10.31
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
2,056 3,166 3,105 3,131 3,935 4,606 5,393 5,306 5,653 6,229 6,672 7,345
1,653 2,159 2,490 2,488 3,061 3,383 3,913 4,432 4,970 5,296 5,664 6,226
Operating Profit 403 1,007 615 643 874 1,223 1,480 874 682 932 1,008 1,118
OPM % 20% 32% 20% 21% 22% 27% 27% 16% 12% 15% 15% 15%
4 7 2 7 9 -39 87 56 -2 28 56 -12
Interest 4 5 5 3 18 27 16 18 50 56 79 94
Depreciation 44 72 83 105 115 157 183 287 275 273 279 319
Profit before tax 359 936 529 541 749 1,000 1,368 625 355 632 707 694
Tax % 21% 23% 23% 22% 21% 20% 19% 17% 4% 3% 18% 3%
283 720 403 413 583 801 1,146 521 342 616 582 671
EPS in Rs 15.01 38.20 21.39 21.89 31.00 43.97 58.33 26.50 17.40 31.33 29.68 34.33
Dividend Payout % 23% 9% 19% 18% 18% 23% 24% 38% 46% 35% 37% 35%
Compounded Sales Growth
10 Years: 9%
5 Years: 6%
3 Years: 9%
TTM: 10%
Compounded Profit Growth
10 Years: 0%
5 Years: -9%
3 Years: 28%
TTM: 28%
Stock Price CAGR
10 Years: 3%
5 Years: -5%
3 Years: 11%
1 Year: -22%
Return on Equity
10 Years: 16%
5 Years: 11%
3 Years: 13%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 38 38 38 38 38 38 39 39 39 39 39 39
Reserves 847 1,560 1,865 2,182 2,681 3,182 5,028 5,198 4,331 4,779 5,152 5,636
264 114 89 708 1,128 1,747 584 717 722 513 1,258 1,430
493 718 698 1,013 931 1,022 1,058 1,167 1,090 1,114 1,324 1,658
Total Liabilities 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773 8,763
547 708 799 993 1,158 1,552 1,788 1,798 2,398 2,547 2,524 3,130
CWIP 83 93 396 1,010 1,551 1,846 2,183 2,304 601 524 837 634
Investments 2 87 50 42 49 18 236 118 96 93 127 141
1,009 1,541 1,444 1,896 2,019 2,573 2,502 2,902 3,087 3,281 4,285 4,858
Total Assets 1,641 2,429 2,689 3,941 4,778 5,989 6,709 7,122 6,183 6,446 7,773 8,763

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
172 948 329 312 812 449 1,463 552 724 803 88 783
-256 -307 -486 -884 -756 -731 -840 -372 -448 -321 -568 -506
87 -224 -129 503 59 155 -597 -217 -262 -438 444 -164
Net Cash Flow 3 417 -286 -69 115 -127 26 -37 14 45 -37 113
Free Cash Flow -52 647 348 -495 49 -285 804 128 282 487 -466 290
CFO/OP 60% 114% 73% 70% 112% 56% 115% 77% 115% 88% 16% 79%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 64 40 40 61 45 69 24 56 68 60 77 73
Inventory Days 196 266 269 302 356 417 431 406 315 350 466 462
Days Payable 166 264 213 313 237 220 194 178 145 157 179 154
Cash Conversion Cycle 94 42 96 51 164 266 261 283 237 253 363 381
Working Capital Days 32 36 61 69 24 50 73 74 77 88 87 88
ROCE % 38% 66% 29% 22% 23% 24% 26% 11% 7% 13% 13% 13%

Insights

In beta
Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cumulative ANDA approvals (Final + Tentative)
Number

Log in to view insights

Please log in to see hidden values.

Login
Cumulative ANDA filings
Number
Cumulative US DMF Filings
Number
Number of Manufacturing Facilities
Number
R&D Spend as % of Sales
%
Number of Scientists / R&D Personnel
Number
Field Force Strength (Medical Representatives)
Number
India Branded Business Market Share (IPM)
%
R&D Expenditure (Percentage of Turnover)
% ・Standalone data

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.61% 69.67% 69.68% 69.74% 69.74% 69.74%
4.34% 4.51% 4.52% 4.46% 4.32% 3.94% 4.17% 3.94% 3.96% 4.04% 4.23% 4.26%
13.65% 14.22% 14.51% 15.39% 15.47% 16.05% 16.05% 16.43% 16.46% 16.30% 16.17% 16.17%
12.39% 11.67% 11.36% 10.54% 10.61% 10.38% 10.17% 9.96% 9.91% 9.92% 9.84% 9.83%
No. of Shareholders 97,60789,55285,21276,56774,82991,42993,94491,33689,01389,96987,00086,432

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls